Molecular Cancer Therapeutics Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

About the Cover

Cover Figure


Molecular docking of celastrol with Hsp90 and Hsp90-Cdc37 complex. The chemical structure of celastrol (upper left), ribbon view of the Hsp90-Cdc37 complex (upper right), Hsp90-celastrol binding pocket (middle) and Hsp90-Cdc37-celastrol binding pocket (lower left) are shown. Only amino acid residues close to celastrol are displayed for clarity. Also present is the superimposition of Hsp90-celastrol (brown) complex with the Hsp90-p23/Sba1 (blue) X-ray structure (lower right). The ATP analogue (AMPPNP) is shown and the "lid" segment is colored in yellow for Hsp90-celastrol and pink for Hsp90-p23. For details, see Zhang et al. in this issue.

[Table of Contents]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2008 by the American Association for Cancer Research.